bearing multiple myeloma xenografts (7) . The multiple myeloma tumors that were treated with R3Mab overexpress wild-type FGFR3. It was convincingly demonstrated that the antitumor effect of R3Mab treatment of tumor cells bearing high amounts of wild-type FGFR3 on their cell surface was mediated in part by Ab-dependent cell-mediated cytotoxicity (ADCC). By contrast, ADCC did not seem to play a role in the antitumor effect of R3Mab on human bladder cancer cells, which express at least a 5-fold lower level of wild-type or mutant FGFR3 compared with the multiple myeloma cells studied.
Finally, since similar gain-of-function mutations in FGFR3 cause skeletal dysplasias and other developmental disorders, it will be important in future studies to examine whether R3Mab treatment may prevent or attenuate developmental disorders caused by FGFR3-activating mutations in neonatal murine models of these diseases (10) (11) (12) .
Anti-TNF immunotherapy has revolutionized the treatment of some inflammatory diseases, such as RA. However, a major concern is that patients receiving this therapy have an increased risk of fungal and bacterial infection, particularly of reactivating latent tuberculosis (TB). In this issue of the JCI, in an effort to understand how anti-TNF immunotherapy affects host mechanisms required to control TB, Bruns and colleagues examined the effects of the anti-TNF therapeutic infliximab on Mycobacterium tuberculosis-specific human lymphocytes (see the related article beginning on page 1167). The authors report that a granulysinexpressing CD45RA + subset of effector memory CD8 + T cells that contributes to the killing of intracellular M. tuberculosis is depleted in vivo by infliximab in patients with RA, and that these cells are susceptible to complement-mediated lysis in the presence of infliximab in vitro. The study provides insight into host defense mechanisms that act to control TB infection and how they are affected during anti-TNF immunotherapy for autoimmune disease.
TNF is a pleiotropic cytokine that plays a critical but incompletely understood role in immunity to Mycobacterium tuberculosis and other intracellular bacterial and fungal pathogens. TNF is not only essential for immune control of tuberculosis (TB), it has also been implicated in the immunopathology of the disease (1). While considerable knowledge of the actions of TNF in immunity to M. tuberculosis has been gained from studies in animal models, we have also gained a deeper understanding of TNF's contributions to the control of TB in humans through the use of TNF-neutralizing drugs for certain chronic inflammatory diseases. While these agents are highly efficacious for the treatment of RA, ankylosing spondylitis, psoriatic arthritis, and Crohn disease, they also promote reactivation (and possibly acquisition) of intracellular pathogens, including M. tuberculosis, resulting in potentially life-threatening infections. Since the early reports of TB in patients treated with infliximab, an anti-TNF monoclonal antibody, described abnormalities in granulomas (2) , much of the work to elucidate the mechanisms of TB reactivation has focused on the roles of TNF in the formation and maintenance of these structures. Granulomas are thought to contribute to control of intramacro-phage pathogens by providing a local environment in which APCs and lymphocytes interact to suppress progressive growth of the pathogen. In the current issue of the JCI, Bruns et al. describe an additional mechanism for susceptibility to progressive TB in individuals treated with infliximab (3). Using PBMCs from tuberculin skin test-positive subjects, Bruns et al. identified granulysin-rich CD8 + CD45RA + CCR7 -effector memory T cells (CD8 + T EMRA cells) as a major subset of antimycobacterial effector cells and found that T EMRA cells are selectively depleted by infliximab therapy in patients with RA. Here we discuss the impact of these findings as they relate to the existing knowledge of CD8 + T cells and TNF in immunity to M. tuberculosis.
CD8 + T cells and immunity to M. tuberculosis
Cell-mediated immunity is critical for control of M. tuberculosis infection, and it has long been acknowledged that CD4 + T cells are important mediators of immunity to M. tuberculosis. More recently, M. tuberculosisspecific CD8 + T cells have been increasingly recognized, but their significance remains incompletely understood, especially in humans. CD8 + T cells are thought to limit mycobacterial growth directly through the killing of infected cells (4, 5) , as well as indirectly through secretion of cytokines that promote activation of macrophages and chemokines that coordinate cell recruitment. Mice deficient in MHC class I molecules, and thus deficient in CD8 + T cells due to the absence of positive selection, have higher burdens of M. tuberculosis in the lungs and a modest decrease in survival (6) . This is in contrast to CD4 + T cell-deficient mice, which display more rapidly progressive bacterial growth and a sharp decline in survival (6) . These studies and others imply that CD8 + T cells are less crucial during the acute phase of M. tuberculosis infection, but are indispensable during the chronic phase of infection, and therefore may help prevent reactivation of TB (7, 8) . When evaluating the contribution of CD8 + T cells to M. tuberculosis immunity, it is important to note that mice lack granulysin, a cytolytic granule protein that contributes to killing of M. tuberculosis by human CD8 + T cells (4) . Therefore, murine studies may undervalue the importance of the antimycobacterial properties of CD8 + T cell subsets compared with their roles in human immunity. Human studies are more limited in number, but in vitro experiments provide evidence that CD8 + T cells can control M. tuberculosis through killing of infected macrophages and subsequent death of the bacteria, as well as by direct killing of mycobacteria by secreted granulysin (4, 5, 9). Bruns et al. (3) found in their assays that T EMRA cells stain for granulysin with high frequency and display the highest levels of both cytotoxicity and antimycobacterial activity compared with other T cell subsets.
TNF blockade and progression of M. tuberculosis
The authors go beyond defining T EMRA cells as potentially important antimycobacterial effector cells, to address the consequences of TNF blockade on these cells and on mycobacterial growth in cultured cells (3) . In doing so, they reveal what we believe to be a novel potential mechanism for TNF neutralization to promote progression of TB. Previous studies in mice and in zebrafish embryos have revealed variable increases in bacillary load in the absence of TNF, ranging from small changes to multiple orders of magnitude (10) (11) (12) (13) . These observations indicated that TNF contributes directly to control of mycobacteria in granuloma macrophages (10) and may also function indirectly to suppress mycobacterial growth by modulating formation and/or maintenance of granulomas. Additional evidence suggests that TNF blockade may impair mycobacterial control as a result of effects on T lymphocytes. TNF blockade has previously been shown to induce production of Tregs via TGF-β in patients with RA (14, 15) , and in mice infected with M. tuberculosis, depletion of Tregs leads to improved control of mycobacterial growth (16) . Bruns et al. provide evidence that TNF blockade may also promote reactivation of TB through selective reduction of T EMRA cells (3) . As a mechanism for their observation that T EMRA cells in peripheral blood are depleted following infliximab therapy, the authors demonstrate that T EMRA cells from RA patients possess high levels of membrane-bound (presumably transmembrane) TNF compared with healthy controls and are susceptible to in vitro complement-mediated lysis in the presence of infliximab. Additionally, PBMCs from patients receiving infliximab therapy displayed diminished capacity to limit mycobacterial growth in culture, an impairment that was rescued by the addition of autologous CD8 + T EMRA cells, to a slightly lesser extent by CD8 + CCR7 -CD45RA -effector memory T cells, but not by circulating central memory CD8 + T cells.
Implications for future study
As with any provocative results, the findings reported by Bruns et al. (3) raise several questions, with implications for understanding immunity to TB and with practical application to clinical medicine. First, do infliximab and etanercept differ in their ability to deplete T EMRA cells? Infliximab, a monoclonal antibody to TNF, and etanercept, a soluble TNF receptor, are both TNF-neutralizing agents used in the treatment of RA and other inflammatory conditions. For unclear reasons, infliximab causes significantly more infectious complications, including reactivation of M. tuberculosis, than does etanercept; this has been attributed by some to the differential ability of these agents to bind membrane TNF. Several studies have found that apoptosis ensues upon binding of infliximab to membrane TNF on T cells (17) , monocytes (18) , and cells transfected to express membrane TNF (19, 20) , which may lead to a reduction in the number of antimycobacterial effector cells and/or to dissolution of granulomas. In contrast, etanercept does not cause apoptosis of cells that express membrane TNF (17, 19, 20) . Additionally, cell lines transfected with membrane TNF have been used to evaluate complementdependent cytotoxicity (CDC) and antibody-dependent, cell-mediated cytotoxicity (ADCC); while both etanercept and infliximab lead to ADCC, only infliximab induces CDC (20, 21) . Consistent with these results, Bruns et al. (3) revealed that T EMRA cells are susceptible to CDC in the presence of infliximab (Figure 1) . If etanercept does not cause CDC of T EMRA cells, this outcome would suggest that the differential risk of reactivation of TB with these agents may be caused, at least in part, by relative differences in depletion of T EMRA cells. Likewise, if etanercept does not deplete T EMRA cells to the same extent as does infliximab, this could at least partially explain the therapeutic differences observed with these 2 drugs. While both drugs are equally efficacious for the treatment of RA, infliximab is superior to etanercept in the treatment of other chronic inflammatory diseases, especially Crohn disease (22) . If selective reduction of T EMRA cells does not occur following etanercept therapy, this finding could provide insight into differences in the immunopathology of these inflammatory conditions. In contrast, if etanercept does deplete T EMRA cells to the same extent as does infliximab, it would weaken the case that T EMRA cells are an essential element of protective immunity against TB.
Second, how long does infliximab-mediated depletion of T EMRA cells persist? The frequency of progressive TB in people treated with infliximab is highest in the first 90 days after initiating the therapy (23) , but the studies by Bruns et al. were limited to a single time point 2 weeks after initiating therapy (3). Additional studies of the duration of depletion of T EMRA cells after anti-TNF therapy should shed further light on the roles of these cells in protection against TB.
Third, what are the antigens recognized by T EMRA cells, and what determines differentiation of CD8 + effector cells into T EMRA cells rather than CD45RA -effector memory T cells? Answers to these questions could provide guidance in the design of improved TB vaccines by delineating optimal antigens and adjuvants and might also provide insight into the mechanisms of differential susceptibility and resistance to TB in populations and in individuals. In addition, they may identify Ag-specific T EMRA cells as potential surrogate markers of vaccine efficacy and thereby provide improved predictive information in the design and evaluation of clinical trials of novel TB vaccines.
Finally, while the findings reported by Bruns et al. clearly demonstrate that T EMRA cells are targets of the anti-TNF action of infliximab (3), they do not provide proof that TNF has an essential function in the development, maintenance, or effector functions of this interesting subset of CD8 + T cells. If membrane TNF is simply a bystander, then future development of agents that block TNF activities without depleting T EMRA cells may provide for safer therapy of chronic inflammatory diseases.
